Table 16 (Abstract P238). See text for description
From: Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part two
| Â | PharMetrics | MarketScan | ||
|---|---|---|---|---|
Baseline characteristics* | Abatacept-treated patients n = 225 | Other bDMARD-treated patients n = 1346 | Abatacept-treated patients n = 238 | Other bDMARD-treated patients n = 1252 |
Female | 183 (81.3) | 948 (70.4) | 195 (81.9) | 927 (74.0) |
Age, mean (SD) | 13.17 (3.2) | 10.86 (3.5) | 12.36 (3.2) | 11.03 (3.5) |
Baseline co-morbidities | Â | Â | Â | Â |
Asthma | 18 (8.0) | 63 (4.7) | 21 (8.8) | 46 (3.7) |
Cardiovascular disease | 22 (9.8) | 53 (3.9) | 18 (7.6) | 49 (3.9) |
Hospitalized infections | Â | Â | Â | Â |
Uveitis | 14 (6.2) | 28 (2.1) | 10 (4.2) | 27 (2.2) |
Biologic DMARDs | 22 (9.8) | 140 (10.4) | 22 (9.2) | 159 (12.7) |
Non-biologic DMARDs | 109 (48.4) | 2 (0.1) | 84 (35.3) | 2 (0.2) |
Inpatient visits, mean (SD) | 139 (61.8) | 614 (45.6) | 105 (44.1) | 476 (38.0) |
Outpatient visits, mean (SD) | 0.21 (0.8) | 0.07 (0.4) | 0.18 (0.8) | 0.07 (0.3) |
| Â | 12.01 (10.2) | 7.89 (9.0) | 11.63 (10.7) | 7.43 (8.9) |
Outcomes | ||||
HIs, IR (95% CI) Uveitis, IR (95% CI) | 1.4 (0.3, 4.1) 1.6 (0.5, 3.8) | 1.7 (1.1, 2.5) 3.1 (2.4, 3.9) | 2.4 (0.9, 5.3) 3.6 (1.7, 6.9) | 1.6 (1.0, 2.4) 3.3 (2.5, 4.2) |